SG11201502599TA - Non-cross-linked acellular pertussis antigens for use in combination vaccines - Google Patents

Non-cross-linked acellular pertussis antigens for use in combination vaccines

Info

Publication number
SG11201502599TA
SG11201502599TA SG11201502599TA SG11201502599TA SG11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA SG 11201502599T A SG11201502599T A SG 11201502599TA
Authority
SG
Singapore
Prior art keywords
cross
non
use
combination vaccines
acellular pertussis
Prior art date
Application number
SG11201502599TA
Inventor
Lorenzo Tarli
Mario Contorni
Alessandro Bartalesi
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261713356P priority Critical
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to PCT/EP2013/071372 priority patent/WO2014057132A1/en
Publication of SG11201502599TA publication Critical patent/SG11201502599TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse Transcribing DNA Viruses
    • C12N2730/00011Reverse Transcribing DNA Viruses
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/30011Nodaviridae
    • C12N2770/30034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • Y02A50/466The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
SG11201502599TA 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines SG11201502599TA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201261713356P true 2012-10-12 2012-10-12
PCT/EP2013/071372 WO2014057132A1 (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Publications (1)

Publication Number Publication Date
SG11201502599TA true SG11201502599TA (en) 2015-05-28

Family

ID=49326692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201502599TA SG11201502599TA (en) 2012-10-12 2013-10-11 Non-cross-linked acellular pertussis antigens for use in combination vaccines

Country Status (13)

Country Link
US (1) US20150273036A1 (en)
EP (1) EP2906239A1 (en)
JP (1) JP6440619B2 (en)
KR (1) KR20150065878A (en)
CN (1) CN104918634A (en)
AU (1) AU2013328548A1 (en)
BR (1) BR112015008040A2 (en)
CA (1) CA2886938A1 (en)
IL (1) IL238023D0 (en)
MX (1) MX2015004652A (en)
RU (1) RU2015111987A (en)
SG (1) SG11201502599TA (en)
WO (1) WO2014057132A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2016168815A1 (en) * 2015-04-16 2016-10-20 Iventprise LLC Bordetella pertussis immunogenic vaccine compositions

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
EP0114787B1 (en) 1983-01-25 1991-09-25 Ciba-Geigy Ag Peptide derivatives
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4624918A (en) 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa Glycoprotein conjugate to attivita 'trivalent immunogenic
IT1223334B (en) * 1987-11-02 1990-09-19 Sclavo Spa Immunologically active polypeptides with a toxicity 'altered useful for the preparation of a pertussis vaccine
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric A polymer mixture with polyester, and paraffin sulfonate, articles formed therefrom.
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
DE68907045D1 (en) 1989-01-17 1993-07-15 Eniricerche Spa Synthetic peptides and their use as a general carrier for the preparation of immunogenic conjugates that are suitable for the development of synthetic vaccines.
AT127347T (en) 1989-04-28 1995-09-15 Sclavo Spa Pertussis toxin mutant, the same producing Bordetella strains and their use as a vaccine against pertussis.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Fiber hemagglutinin of Bordetella pertussis as carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
WO1993024148A1 (en) 1992-05-23 1993-12-09 Smithkline Beecham Biologicals (S.A.) Combined vaccines comprising hepatitis b surface antigen and other antigens
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9216351D0 (en) 1992-07-31 1992-09-16 Wellcome Found Vaccine production
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
JP3828145B2 (en) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン Activation method of soluble carbohydrates using new cyanide reagents for the preparation of an immunogenic construct
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
PT914153E (en) * 1996-07-02 2007-01-31 Aventis Pasteur Multivalent dtp-polio vaccines
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
DE69612198T3 (en) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. A vaccine composition, comprising an Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminum phosphate
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DK1028750T3 (en) * 1997-09-15 2006-05-22 Sanofi Pasteur Msd A process for the preparation of multivalent vaccines
AU755445B2 (en) 1998-05-07 2002-12-12 Corixa Corporation Adjuvant composition and methods for its use
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
SI1946769T1 (en) 2000-06-29 2012-07-31 Smithkline Beecham Biolog Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
CA2498847C (en) 2002-09-13 2014-10-28 Chiron Corporation Group b streptococcus vaccine
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
AT512670T (en) * 2004-04-30 2011-07-15 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (en) 2005-08-19 2013-01-11 Array Biopharma Inc Aminodiazepines as toll-like receptor modulators
AR056591A1 (en) 2005-10-28 2007-10-10 Vaxinnate Corp Ligands for receptor polypeptides similar toll 4 (TLR4)
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
US20100183667A1 (en) 2006-10-12 2010-07-22 Glaxo Smithkline Biologicals S.A. Vaccine Comprising an Oil in Water Emulsion Adjuvant
AU2006327023A1 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion oil in water thermo
DK2038290T3 (en) 2006-07-07 2013-12-02 Gilead Sciences Inc Modulators of Toll-like receptor 7
SI2066344T1 (en) 2006-09-07 2011-09-30 Glaxosmithkline Biolog Sa Inactivated Poliovirus combination vaccine
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
TW200914042A (en) * 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
PE12362009A1 (en) 2007-11-22 2009-09-16 Astrazeneca Ab Pyrimidine derivatives as immunomodulators TLR7
US8092813B1 (en) 2007-12-28 2012-01-10 Novartis Ag Polychlorinated biphenyls and squalene-containing adjuvants
RS54190B1 (en) 2008-03-03 2015-12-31 Novartis Ag Compounds and compositions as tlr activity modulators
RS53059B (en) 2008-03-24 2014-04-30 4Sc Discovery Gmbh Novel substituted imidazoquinolines
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
BRPI0917716A2 (en) 2008-08-28 2019-09-03 Novartis Ag squalene production from hyperproductive yeasts
CN102762226A (en) 2009-06-10 2012-10-31 诺华有限公司 Benzonaphthyridine-containing vaccines
MX2012005598A (en) 2009-12-03 2012-05-29 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants.
ES2573710T3 (en) 2009-12-03 2016-06-09 Novartis Ag Circulation of components during homogenization and microfluidization of emulsions
SI2506833T1 (en) 2009-12-03 2014-07-31 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
JP5946188B2 (en) 2010-05-12 2016-07-05 ノバルティス アーゲー Improved method for preparing squalene
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US20120177681A1 (en) 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators

Also Published As

Publication number Publication date
WO2014057132A1 (en) 2014-04-17
JP6440619B2 (en) 2018-12-19
MX2015004652A (en) 2015-08-05
AU2013328548A1 (en) 2015-05-07
US20150273036A1 (en) 2015-10-01
CN104918634A (en) 2015-09-16
JP2015533148A (en) 2015-11-19
CA2886938A1 (en) 2014-04-17
BR112015008040A2 (en) 2017-07-04
IL238023D0 (en) 2015-05-31
RU2015111987A (en) 2016-12-10
EP2906239A1 (en) 2015-08-19
KR20150065878A (en) 2015-06-15

Similar Documents

Publication Publication Date Title
EP2895111A4 (en) Mitral valve inversion prostheses
GB201101662D0 (en) Silicone wound dressing laminate
PT2724741T (en) Inhalation device for use in aerosol therapy
HK1193971A1 (en) Beauty device
EP2714073A4 (en) In situ antigen-generating cancer vaccine
RU2017101868A (en) Prostat-associated antigens and immunotherapeutic schemes based on vaccines
PT2492392E (en) Method for preparing aramid paper and the aramid paper obtained therefrom
EP2707031A4 (en) Protein-active agent conjugates and method for preparing the same
EP2776233A4 (en) Methods and apparatus for 3d fabrication
EP2838468A4 (en) Intra-oral light-therapy apparatuses and methods for their use
EP2871997A4 (en) Motorized nail file
IL232226D0 (en) Albumin binding antobodies and binding fragments thereof
HRP20181102T1 (en) Vaccines for hsv-2
EP2706991A4 (en) Multiple antigen presenting immunogenic composition, and methods and uses thereof
HK1208150A1 (en) Vaccine
IL236650D0 (en) Mycobacterial antigen vaccine
LT2785387T (en) Wound dressing for use in vacuum therapy
IL237609D0 (en) Temporary dental prosthesis for use in developing final dental prosthesis
PL2647387T3 (en) Vaccine Composition
IL236040A (en) Berberine for use in improving gut microbiota population
HK1207284A1 (en) Mycoplasma hyopneumoniae vaccine
SI2510845T1 (en) Grinding device
EP2716908A4 (en) Natural energy extraction apparatus
HK1231412A1 (en) Immunogenic composition
EP2956544A4 (en) Cancer vaccines and vaccination methods